inclusion criteria: * adult patient age between 18-65 years old * has confirmed sars-cov-2 infection by rt-pcr method using sample collected from nasopharyngeal swab (np) and oropharyngeal swab (op) with ct value in either one of the following cases 1. ct ≤ 26 if the subject has rt-pcr performed as part of screening procedures 2. ct ≤ 24 if the subject has had rt-pcr performed before admission and the time between the sample collection for rt-pcr and randomization is ≤ 24 hours * has been admitted for medical care at the investigational sites * in case of symptomatic patient, date of symptoms onset is ≤ 7 days prior to randomization. in case of asymptomatic patient, the first date of positive result from rt-pcr or antigen test kit for sars-cov-2 is ≤ 7 days prior to randomization. * qualified for the criteria to receive favipiravir for covid-19 treatment according to guidelines on clinical practice, diagnosis, treatment, and prevention of healthcare-associated infection for covid-19 in thailand in either one of the following cases 1. will start receiving favipiravir during the study period or 2. has received favipiravir no more than 24 hours before receiving the investigational drug * asymptomatic or has mild to moderate covid-19 as defined in section 7.2.2. * willing to participate in the study and able to provide written informed consent * women of childbearing potential must agree to either abstinence or use at least one primary form of contraception from the time of screening through d28.

inclusion criteria: * adult patient age between 18-65 years old * has confirmed sars-cov-2 infection by rt-pcr method using sample collected from nasopharyngeal swab (np) and oropharyngeal swab (op) with ct value in either one of the following cases 1. ct ≤ 26 if the subject has rt-pcr performed as part of screening procedures 2. ct ≤ 24 if the subject has had rt-pcr performed before admission and the time between the sample collection for rt-pcr and randomization is ≤ 24 hours * has been admitted for medical care at the investigational sites * in case of symptomatic patient, date of symptoms onset is ≤ 7 days prior to randomization. in case of asymptomatic patient, the first date of positive result from rt-pcr or antigen test kit for sars-cov-2 is ≤ 7 days prior to randomization. * qualified for the criteria to receive favipiravir for covid-19 treatment according to guidelines on clinical practice, diagnosis, treatment, and prevention of healthcare-associated infection for covid-19 in thailand in either one of the following cases 1. will start receiving favipiravir during the study period or 2. has received favipiravir no more than 24 hours before receiving the investigational drug * asymptomatic or has mild to moderate covid-19 as defined in section 7.2.2. * willing to participate in the study and able to provide written informed consent * women of childbearing potential must agree to either abstinence or use at least one primary form of contraception from the time of screening through d28.

inclusion criteria: adult patient age between 18-65 years old has confirmed sars-cov-2 infection by rt-pcr method using sample collected from nasopharyngeal swab (np) and oropharyngeal swab (op) with ct value in either one of the following cases ct ≤ 26 if the subject has rt-pcr performed as part of screening procedures ct ≤ 24 if the subject has had rt-pcr performed before admission and the time between the sample collection for rt-pcr and randomization is ≤ 24 hours has been admitted for medical care at the investigational sites in case of symptomatic patient, date of symptoms onset is ≤ 7 days prior to randomization. in case of asymptomatic patient, the first date of positive result from rt-pcr or antigen test kit for sars-cov-2 is ≤ 7 days prior to randomization. qualified for the criteria to receive favipiravir for covid-19 treatment according to guidelines on clinical practice, diagnosis, treatment, and prevention of healthcare-associated infection for covid-19 in thailand in either one of the following cases will start receiving favipiravir during the study period or has received favipiravir no more than 24 hours before receiving the investigational drug asymptomatic or has mild to moderate covid-19 as defined in section 7.2.2. willing to participate in the study and able to provide written informed consent women of childbearing potential must agree to either abstinence or use at least one primary form of contraception from the time of screening through d28.

inclusion criteria: adult patient age between 18-65 years old has confirmed sars-cov-2 infection by rt-pcr method using sample collected from nasopharyngeal swab (np) and oropharyngeal swab (op) with ct value in either one of the following cases ct ≤ 26 if the subject has rt-pcr performed as part of screening procedures ct ≤ 24 if the subject has had rt-pcr performed before admission and the time between the sample collection for rt-pcr and randomization is ≤ 24 hours has been admitted for medical care at the investigational sites in case of symptomatic patient, date of symptoms onset is ≤ 7 days prior to randomization. in case of asymptomatic patient, the first date of positive result from rt-pcr or antigen test kit for sars-cov-2 is ≤ 7 days prior to randomization. qualified for the criteria to receive favipiravir for covid-19 treatment according to guidelines on clinical practice, diagnosis, treatment, and prevention of healthcare-associated infection for covid-19 in thailand in either one of the following cases will start receiving favipiravir during the study period or has received favipiravir no more than 24 hours before receiving the investigational drug asymptomatic or has mild to moderate covid-19 as defined in section 7.2.2. willing to participate in the study and able to provide written informed consent women of childbearing potential must agree to either abstinence or use at least one primary form of contraception from the time of screening through d28.

None

None

inclusion criteria: adult patient age between 18-65 years old has confirmed sars-cov-2 infection by rt-pcr method using sample collected from nasopharyngeal swab (np) and oropharyngeal swab (op) with ct value in either one of the following cases ct ≤ 26 if the subject has rt-pcr performed as part of screening procedures ct ≤ 24 if the subject has had rt-pcr performed before admission and the time between the sample collection for rt-pcr and randomization is ≤ 24 hours has been admitted for medical care at the investigational sites in case of symptomatic patient, date of symptoms onset is ≤ 7 days prior to randomization. in case of asymptomatic patient, the first date of positive result from rt-pcr or antigen test kit for sars-cov-2 is ≤ 7 days prior to randomization. qualified for the criteria to receive favipiravir for covid-19 treatment according to guidelines on clinical practice, diagnosis, treatment, and prevention of healthcare-associated infection for covid-19 in thailand in either one of the following cases will start receiving favipiravir during the study period or has received favipiravir no more than 24 hours before receiving the investigational drug asymptomatic or has mild to moderate covid-19 as defined in section 7.2.2. willing to participate in the study and able to provide written informed consent women of childbearing potential must agree to either abstinence or use at least one primary form of contraception from the time of screening through d28.

inclusion criteria: adult patient age between 18-65 years old has confirmed sars-cov-2 infection by rt-pcr method using sample collected from nasopharyngeal swab (np) and oropharyngeal swab (op) with ct value in either one of the following cases ct ≤ 26 if the subject has rt-pcr performed as part of screening procedures ct ≤ 24 if the subject has had rt-pcr performed before admission and the time between the sample collection for rt-pcr and randomization is ≤ 24 hours has been admitted for medical care at the investigational sites in case of symptomatic patient, date of symptoms onset is ≤ 7 days prior to randomization. in case of asymptomatic patient, the first date of positive result from rt-pcr or antigen test kit for sars-cov-2 is ≤ 7 days prior to randomization. qualified for the criteria to receive favipiravir for covid-19 treatment according to guidelines on clinical practice, diagnosis, treatment, and prevention of healthcare-associated infection for covid-19 in thailand in either one of the following cases will start receiving favipiravir during the study period or has received favipiravir no more than 24 hours before receiving the investigational drug asymptomatic or has mild to moderate covid-19 as defined in section 7.2.2. willing to participate in the study and able to provide written informed consent women of childbearing potential must agree to either abstinence or use at least one primary form of contraception from the time of screening through d28.